Literature DB >> 9237426

Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom.

M Le Borgne1, P Marchand, M Duflos, B Delevoye-Seiller, S Piessard-Robert, G Le Baut, R W Hartmann, M Palzer.   

Abstract

In the challenge to develop potent inhibitors of aromatase for reducing the levels of estrogens, we found that azolyl-substituted indoles inhibit aromatase activity, 3-(1-Azolylmethyl)-1H-indoles 9-15 and 3-(1-azolyl-1-phenylmethyl)-1H-indoles 22-25 were prepared, and tested on their ability to inhibit P450 arom. Analysis of the inhibitory effect exerted by several derivatives (11, 12, 22, and 23) on microsomal aromatase in vitro activity indicates that azolyl-substituted indoles containing an imidazole moiety are more potent inhibitors than triazole derivatives. In the first series, the introduction of the N-benzyl moiety has been found to enhance the inhibitory profile of these 3-(1-azolylmethyl)-1H-indole derivatives. The corresponding 4-fluoro derivative 12 displays the highest inhibitory activity (IC50 = 0.0718 microM) of all investigated compounds; thus, 12 is 258 times as potent as aminoglutethimide (AG). The presence of a chloro grouping in para position of the phenyl ring in compounds 22 and 24 exerts a positive effect only in the triazol-l-yl sub-series: compound 25 is 4-fold more potent than 24.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237426     DOI: 10.1002/ardp.19973300506

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  8 in total

1.  First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Carsten A Vock; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2010-10-22       Impact factor: 4.345

2.  Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Jörg Haupenthal; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2011-06-03       Impact factor: 4.345

3.  Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors.

Authors:  Partha Pratim Roy; Kunal Roy
Journal:  J Mol Model       Date:  2010-03-01       Impact factor: 1.810

4.  Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.

Authors:  Allan M Prior; Xufen Yu; Eun-Jung Park; Tamara P Kondratyuk; Yan Lin; John M Pezzuto; Dianqing Sun
Journal:  Bioorg Med Chem Lett       Date:  2017-11-06       Impact factor: 2.823

5.  Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis.

Authors:  Yagmur Muftuoglu; Gabriela Mustata
Journal:  Reprod Biol Endocrinol       Date:  2011-06-21       Impact factor: 5.211

6.  Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).

Authors:  Alessandro Spadaro; Matthias Negri; Sandrine Marchais-Oberwinkler; Emmanuel Bey; Martin Frotscher
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

7.  Halogen-Based 17β-HSD1 Inhibitors: Insights from DFT, Docking, and Molecular Dynamics Simulation Studies.

Authors:  Arulsamy Kulandaisamy; Murugesan Panneerselvam; Rajadurai Vijay Solomon; Madhavan Jaccob; Jaganathan Ramakrishnan; Kumaradhas Poomani; Muralikannan Maruthamuthu; Nagendran Tharmalingam
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

8.  Synthesis, Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols.

Authors:  Nicolas Lebouvier; Fabrice Pagniez; Young Min Na; Da Shi; Patricia Pinson; Mathieu Marchivie; Jean Guillon; Tarek Hakki; Rita Bernhardt; Sook Wah Yee; Claire Simons; Marie-Pierre Lézé; Rolf W Hartmann; Angélique Mularoni; Guillaume Le Baut; Isabelle Krimm; Ruben Abagyan; Patrice Le Pape; Marc Le Borgne
Journal:  Pharmaceuticals (Basel)       Date:  2020-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.